GM said in a statement it is making the move through a private placement to institutional investors. The shares came about through a strategic alliance last year in an effort to shore up the French automaker Peugeot. A GM official says in a statement that the mission was accomplished.
"Our equity stake was planned to support PSA in their efforts to raise capital at the time of the creation of the GM and PSA alliance, and that support is no longer needed," said GM Vice Chairman Steve Girsky. "The alliance remains strong with our focus on joint vehicle programs, cross manufacturing, purchasing, and logistics. We're making good progress while remaining open to new opportunities."
Top Consumer Service Companies To Own In Right Now: Cyberonics Inc (CYBX)
Cyberonics, Inc. (Cyberonics), incorporated in 1987, is a medical device company. The Company is engaged in the design, development, sales and marketing of implantable medical devices that provide a neuromodulation therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression (TRD) and other device solutions for the management of epilepsy.VNS Therapy System includes an implantable pulse generator to provide stimulation to the vagus nerve; a lead that connects the generator to the vagus nerve; equipment to assist with implantation surgery; equipment to assist with setting the stimulation parameters for each patient; instruction manuals, and magnets to suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The VNS Therapy System consists of a pulse generator, a bipolar lead, a programming wand and software and a tunneling tool.
The United States Food and Drug Administration (FDA) approved the Company's VNS Therapy System in July 1997 for use as an adjunctive therapy in epilepsy patients over 12 years of age for reducing the frequency of partial onset seizures that are refractory or resistant to antiepileptic drugs. Regulatory bodies in Canada, the European Economic Area, certain countries in Eastern Europe, Russia, South America, Africa, Australia and certain countries in Asia, including Japan, China and Taiwan, have approved the VNS Therapy System for the treatment of epilepsy, many without age restrictions or seizure-type limitations. In July 2005, the FDA approved the Company's VNS Therapy System for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a depressive episode and have not had an adequate response to four or more adequate anti-depressant treatments. Regulatory bodies in the European Economic Area, Canada and Israel have approv! ed the Company's VNS Therapy System for the treatment of chronic or recurrent depression in patients who are in a treatment-resistant or treatment-intolerant depressive episode without age restrictions.
In February 2011, the Company announced FDA approval of its fifth generation generator, the AspireHC generator. In August 2011, the Company announced that the Company discovered a hardware-related design issue with the AspireHC Model 105 and AspireSR (Seizure Response) Model 106 generators. In December 2011, the FDA approved the Company's re-designed AspireHC generator, and the Company resumed its limited commercial release of the generator in the United States.
Pulse Generator
The pulse generator is an implantable, programmable signal generator designed to be coupled with the bipolar lead to deliver mild electrical pulses to the vagus nerve. The pulse generator is a battery-powered device. Before or upon depletion of the battery, the pulse generator may be removed and a new generator implanted in a short, outpatient procedure. The Model 102 (Pulse), Model 102R (Pulse Duo ), Model 103 (Demipulse), Model 104 (Demipulse Duo) and Model 105 (AspireHC), are the VNS Therapy pulse generators the Company offers and are similar in design and manufactures to a cardiac pacemaker.
Bipolar Lead
The bipolar lead conducts the electrical signal from the pulse generator to the vagus nerve. The lead incorporates electrodes, which are self-sizing, minimizing mechanical trauma to the nerve. The lead's two electrodes and anchor tether wrap around the vagus nerve, and the connector end is tunneled subcutaneously to the upper chest area, where it attaches to the pulse generator. The Company offers three lead models in the United States. The leads are available in two inner spiral diameter sizes to ensure optimal electrode placement on different-sized nerves.
Programming Wand and Software
The Company's programming wand and software are us! ed to int! errogate the implanted pulse generator and to transmit programming information from a handheld computer to the pulse generator via an inductive coupling. Programming capabilities include modification of the pulse generator's programmable parameters (pulse width, amplitude and frequency and stimulation ON and OFF intervals) and storage and retrieval of telemetry data.
Tunneling Tool
The tunneling tool is a single use, sterile, disposable surgical tool designed to be used during surgical placement of the bipolar lead. The tool is used for subcutaneous tunneling of the lead between the nerve site in the neck and the pulse generator site in the upper chest area.
Accessory Pack
The accessory pack includes two resistor assemblies used to test the function of the device prior to implantation, the bipolar lead tie-downs and one hex screwdriver. The patient kit includes two magnets, one watch-style and one pager-style.
The Company competes with Medtronic, Inc., NeuroSigma Inc. and CerboMed GmbH.
Advisors' Opinion:- [By James E. Brumley]
Investors who were hoping things would work out for epilepsy treatment company Cyberonics, Inc. (NASDAQ:CYBX) can cross CYBX off their list of epilepsy-oriented stocks to buy, as they did with Acorda Therapeutics Inc. (NASDAQ:ACOR) about a month ago. ACOR saw its epilepsy drug Plumiaz rejected by the FDA in early May, while CYBX announced this morning that the coming fiscal year's (beginning in April) revenue would be weaker than first expected as sales of its epileptic control implant device didn't look quite as promising as hoped.
- [By Roberto Pedone]
Another potential earnings short-squeeze candidate is implantable medical devices player Cyberonics (CYBX), which is set to release numbers on Thursday after the market close. Wall Street analysts, on average, expect Cyberonics to report revenue of $74.05 million on earnings of 55 cents per share.
Read More: 5 Breakout Stocks Under $10 Set to Soar
The current short interest as a percentage of the float for Cyberonics is rather high at 11.6%. That means that out of the 21.65 million shares in the tradable float, 2.52 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 4%, or by about 97,000 shares. If the bears get caught pressing their bets into a strong quarter, then shares of CYBX could easily rip sharply higher post-earnings as the shorts rush to cover some of their trades.
From a technical perspective, CYBX is currently trending above its 50-day moving average and just below its 200-day moving average, which is neutral trendwise. This stock recently formed a double bottom chart pattern at $55.75 to $56.56 a share. Following that bottom, shares of CYBX have started to trend back above its 50-day moving average of $59.83 a share and it's quickly moving within range of triggering a near-term breakout trade above some key overhead resistance levels.
If you're bullish on CYBX, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $63.65 to $64.08 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 228,522 shares. If that breakout materializes post-earnings, then CYBX will set up to re-test or possibly take out its next major overhead resistance levels at $67.12 to $69.18 a share, or even $72 to its 52-week high at $73.52 a share.
I would avoid CYBX or look for short-biased trades if after earnin
Top Logistics Stocks For 2014: China Southern Airlines Company Limited(ZNH)
China Southern Airlines Company Limited provides commercial airline services in the People's Republic of China, Hong Kong, Macau, Taiwan, and internationally. It principally engages in the provision of passenger, air cargo, and mail airline services. The company also offers logistics services; air catering services; property management services; aircraft and engine repair and maintenance services; pilot training services; flight simulation services; and airport ground services. As of December 31, 2010, it had a fleet of 422 aircraft, as well as a network reaching 898 destinations connecting 169 countries and regions, and cities worldwide. The company was founded in 1995 and is headquartered in Guangzhou, the People?s Republic of China. China Southern Airlines Company Limited operates as a subsidiary of China Southern Air Holding Company.
Advisors' Opinion:- [By Belinda Cao]
The Bloomberg China-US Equity Index (CH55BN) of the most-traded Chinese companies in the U.S. slumped 3.4 percent last week to a seven-month low of 89.04. The gauge traded at 13.5 times estimated earnings, 3.6 percent below the S&P�� valuation, data compiled by Bloomberg show. China Southern Airlines Co. (ZNH) and China Eastern Airlines Corp. (CEA) lost more than 6 percent April 5, while Home Inns & Hotels Management Inc. (HMIN) tumbled 16 percent in the week.
- [By Lisa Levin]
China Southern Airlines Co (NYSE: ZNH) shares fell 2.47% to reach a new 52-week low of $15.38. China Southern Airlines' PEG ratio is 3.00.
DARA BioSciences (NASDAQ: DARA) shares fell 15.02% to touch a new 52-week low of $1.81. DARA BioSciences' trailing-twelve-month ROA is -66.74%.
- [By MARKETWATCH]
LOS ANGELES (MarketWatch) -- Hong Kong stocks started modestly lower Thursday, tracking broad weakness in Asia, with mainland Chinese banks mixed after the release of November lending data. The Hang Seng Index (HK:HSI) lost 0.2% to 23,288.02, while the Hang Seng China Enterprises Index fell 0.4%. However, the Shanghai Composite (CN:SHCOMP) added 0.1% to 2,205.39 in choppy trade that saw it swing between positive and negative territory. Mainland Chinese banks saw mixed reaction after data showed new yuan-denominated loans rose to 624.6 billion yuan ($102 billion) in November, more than 100 billion yuan above the year-earlier figure and beating market forecasts of between 560 billion yuan and 580 billion yuan, according to the XInhua news agency. Among the top banks, Bank of China Ltd. (HK:3988) (BACHY) was up 0.3%, Bank of Communications Co. (HK:3328) (BKFCF) rose 0.2%, Agricultural Bank of China Ltd. (HK:1288) (ACGBF) traded flat, and Industrial & Commercial Bank of China Ltd. (HK:1398) (IDCBF) fell 0.6%. Shares of Aluminum Corp. of China Ltd. (HK:2600) (ACH) lost 0.7% after saying it could see a drop of up to 37% in output from a key Peruvian copper mine. Angang Steel Co. (HK:347) (ANGGF)
Top Logistics Stocks For 2014: United States 12 Month Oil Fund LP (USL)
The United States 12 Month Oil Fund, LP (US12OF) is a commodity pool that issues limited partnership interests traded on the New York Stock Exchange (NYSE) Arca, Inc. (the NYSE Arca). The investment objective of US12OF is for the daily changes in percentage terms of its units per unit net asset value (NAV) to reflect the daily changes in percentage terms of the spot price of light, sweet crude oil delivered to Cushing, Oklahoma, as measured by the changes in the average of the prices of 12 futures contracts for light, sweet crude oil traded on the New York Mercantile Exchange (the NYMEX) consisting of the near month contract to expire and the contracts for 11 months, for a total of 12 consecutive months contracts, except when the near month contract is within two weeks of expiration, in which case it is measured by the futures contract that is the next month contract to expire and the contracts for 11 consecutive months (the Benchmark Oil Futures Contracts). The Company is managed and controlled by its general partner, United States Commodity Funds LLC (the General Partner). The General Partner is the general partner of US12OF and is responsible for the management of US12OF.
The net assets of US12OF consist primarily of investments in futures contracts for light, sweet crude oil, other types of crude oil, heating oil, gasoline, natural gas, and other petroleum-based fuels that are traded on the NYMEX, ICE Futures or other United States and foreign exchanges (collectively, Oil Futures Contracts). It also invests in other oil interests, such as cash-settled options on Oil Futures Contracts, forward contracts for oil, cleared swap contracts and non-exchange traded (over-the-counter) transactions that are based on the price of oil, other petroleum-based fuels, Oil Futures Contracts and indices based on the foregoing (collectively, Other Oil-Related Investments). For convenience and unless otherwise specified, Oil Futures Contracts and Other Oil-Related Investments collectively are referred to! as oil Interests.
US12OF invests in Oil Interests to the fullest extent possible without being leveraged or unable to satisfy its current or potential margin or collateral obligations with respect to its investments in Oil Futures Contracts and Other Oil-Related Investments. US12OF�� investments in short-term obligations of the United States of two years or less (Treasuries), cash and/or cash equivalents.
Advisors' Opinion:- [By Dan Caplinger]
Another choice is to use ETFs with a longer-term futures strategy. The United States 12-Month Oil Fund (NYSEMKT: USL ) holds equal positions in each of the next 12 futures contracts. That reduces the positive impact of near-term backwardation, but it gives you more exposure to the heavier backwardation that exists further into the future.
Top Logistics Stocks For 2014: Cereplast Inc (CERPQ)
Cereplast, Inc. (Cereplast), incorporated on September 29, 2001, is engaged in developing and commercializing bio-based resins through two product families: Cereplast Compostables Resins, which are compostable, renewable, ecologically sound substitutes for petroleum-based plastics, and Cereplast Sustainables resins (including the Cereplast Hybrid Resins product line), which replaces up to 90% of the petroleum-based content of traditional plastics with materials from renewable resources. The Company primarily conducts its operations through product families, such as Cereplast Compostables resins, Cereplast Hybrid Resins and Cereplast Algae Plastic resins. In October 2011, the Company purchased a manufacturing plant in Assisi (Cannara).
Cereplast Compostables resins are compostable and bio-based, ecologically sound substitutes for petroleum-based plastics targeting primarily compostable bags, single-use food service products and packaging applications. The Company offers 13 commercial grades of Compostable resins in this product line. Cereplast Sustainables resins are partially or fully bio-based, ecologically sound substitutes for fully petroleum-based plastics targeting primarily durable goods, packaging applications. The Company offers six commercial grades of Sustainable resins in this product line. Cereplast Hybrid Resins products replace up to 55% of the petroleum content in conventional plastics with bio-based materials, such as industrial starches sourced from plants. The Hybrid resins line is designed to offer similar properties to traditional polyolefins, such as impact strength and heat deflection temperature, and is compatible with existing converter processes and equipment. The first commercial product with Cereplast Algae Plastic resin is being produced and sold as part of the Company's Sustainables resin family.
The Company's Compostable resins are renewable substitutes for petroleum-based plastics targeting primarily single-use disposables. The Company's Compost! able Resins have been used to produce foodservice ware, including the first line of fully biodegradable and compostable foodservice ware. Cereplast Hybrid Resins uses renewable materials such as starches from corn and tapioca.
Cereplast competes with BASF, Dow Chemical, Lyondell Basell, DuPont, SABIC, Novamont, NatureWorks and Telles.
Advisors' Opinion:- [By Bryan Murphy]
The whole thing may seem a little "out there" at first glance, but truth be told, what Metabolix, Inc. does isn't terribly unusual anymore. It's just a little less sexy than what traders and stock speculators usually want to see and hear with their picks. Kraton Performance Polymers Inc. (NYSE:KRA) and the now-bankrupt Cereplast Inc. (OTCMKTS:CERPQ) are/were in the same business, along with several others. [Don't let the Cereplast bankruptcy filing deter you - it wasn't a lack of opportunity that up-ended CERP.]
No comments:
Post a Comment